No difference in the sensitivity of the human BCL-2 re-programmed leukemic cells to venetoclax was detected when we compared the parental human BCL-2 p185+ B-ALL cells to those that were isolated from the venetoclax-treated recipients (Figure 4E). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.